Profound Medical to Showcase TULSA-PRO Prostate Treatment at 2026 SIR Meeting
Event summary
- Profound Medical's TULSA-PRO system will be featured in multiple presentations at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting, April 11-15 in Toronto.
- Five oral presentations on April 12 will highlight the TULSA Procedure, including a retrospective analysis and a systematic review of its outcomes.
- The CAPTAIN trial comparing TULSA-PRO to robotic prostatectomy will be discussed, with initial perioperative outcomes presented.
- A categorical course on April 13 will focus on prostate interventions, including the TULSA Procedure.
The big picture
Profound Medical's strong presence at the 2026 SIR meeting underscores the growing acceptance of MRI-guided, incision-free therapies in prostate care. The company is positioning TULSA-PRO as a potential mainstream treatment, competing with traditional surgical and radiation options. The focus on clinical data and real-world physician experience suggests a strategic push to validate the procedure's efficacy and safety, which could drive broader adoption.
What we're watching
- Clinical Validation
- How the CAPTAIN trial data will influence physician adoption of TULSA-PRO as a mainstream treatment option.
- Market Expansion
- The pace at which Profound Medical can expand the use of TULSA-PRO beyond prostate cancer to include BPH and other conditions.
- Regulatory Approvals
- Whether Profound Medical can secure additional regulatory approvals for Sonalleve in new clinical applications.
Related topics